MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Mereo BioPharma Group PLC ADR (MREO) is rated C+ (2.6/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-05 | C+ (2.7) | C (2.3) | B (3.3) | C+ (2.5) | C- (1.9) | C+ (2.6) |
| 2026-08-03 | C+ (2.7) | C (2.4) | B (3.2) | C (2.4) | C- (2.0) | C+ (2.5) |
| 2026-08-02 | C+ (2.7) | C (2.4) | B (3.2) | C (2.4) | C- (1.9) | C+ (2.5) |
| 2026-07-29 | C+ (2.5) | C+ (2.5) | B- (3.0) | D (1.2) | D+ (1.5) | C (2.2) |
| 2025-06-30 | C (2.5) | C+ (2.5) | B- (3.0) | D (1.3) | D+ (1.5) | C (2.2) |